See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The U.S. Food and Drug Administration (FDA) has approved a new drug for ...
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioid analgesic designed to treat moderate to ...
Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat ...
BAKERSFIELD, Calif. (KGET) – The FDA has approved a new non-opioid painkiller, a potentially significant step in the ...
HOLLYWOOD, FL - November 06, 2026 - PRESSADVANTAGE - Compassion Behavioral Health has published a new educational ...
Adults on Medicaid who began treatment for a new bout of low back pain with a higher-dose opioid prescription were about two ...
With the goal of informing clinician practice, a new study explores the harms and benefits of continuing and of discontinuing the long-term prescription of opioid medicines to adults with chronic pain ...
The global pain management drugs market is entering a period of strategic change as healthcare providers seek effective pain ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill received ...
Due to the physical contact nature of their occupation, the elite athletes of the National Football League (NFL) often experience pain. However, an analysis of 2021 and 2022 data from the National ...
(The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results